Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

TS-1: Global Drug Analysis (2016-2017) with Forecasts to 2025 - ResearchAndMarkets.com

Research and Markets
Posted on: 15 Feb 18

The "Drug analysis: TS-1" drug pipelines has been added to ResearchAndMarkets.com's offering.

TS-1 (Otsuka/Nordic Group) is an orally available cytotoxic drug that contains gimeracil, oteracil potassium, and tegafur as active ingredients.

TS-1 inhibits DNA replication, a process that is crucial for cell proliferation and tumor growth. Tegafur is a prodrug that is converted to 5-fluorouracil (5-FU) in the body, which is an irreversible inhibitor of thymidylate synthase, an enzyme that is essential for DNA replication. Gimeracil enhances the anti-tumor effects of 5-FU by preventing its degradation within cells. Oteracil potassium reduces the serious gastrointestinal (GI) toxicity caused by 5-FU by inhibiting the phosphorylation of 5-FU in the GI tract.

Key Topics Covered:

Product Profiles

TS-1: Colorectal cancer (CRC)

TS-1: Pancreatic cancer

List of Figures

Figure 1: TS-1 for colorectal cancer - SWOT analysis

Figure 2: Drug assessment summary of TS-1 in colorectal cancer

Figure 3: Drug assessment summary of TS-1 in colorectal cancer

Figure 4: TS-1 sales for colorectal cancer in Japan, 2016-25

Figure 5: TS-1 for pancreatic cancer - SWOT analysis

Figure 6: Drug assessment summary of TS-1 in pancreatic cancer

List of Tables

Table 1: TS-1 drug profile

Table 2: TS-1 pivotal trial data in colorectal cancer

Table 3: TS-1 sales for colorectal cancer in Japan ($m), 2016-25

Table 4: Patients treated with TS-1 in Japan, 2016-25

Table 5: TS-1 drug profile

Table 6: TS-1 pivotal trial data in pancreatic cancer

Table 7: TS-1 other clinical trial data in pancreatic cancer

Table 8: TS-1 ongoing clinical trials in pancreatic cancer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/gdth3n/ts1_global_drug?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215005645/en/

Business Wire
www.businesswire.com

Last updated on: 15/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.